-

Personalis to Participate at Upcoming Investor Conferences

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate at the following investor conferences:

  • 8th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
    Participating on Monday, August 14, 2023
  • Sidoti Virtual Micro Cap Conference
    Presenting on Wednesday, August 16, 2023 at 12:15 p.m. Eastern Time

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and Twitter.

Contacts

Investors:
Caroline Corner
investors@personalis.com
415-202-5678

Media:
pr@personalis.com

Personalis, Inc.

NASDAQ:PSNL

Release Versions

Contacts

Investors:
Caroline Corner
investors@personalis.com
415-202-5678

Media:
pr@personalis.com

More News From Personalis, Inc.

Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the Craig-Hallum 22nd Annual Investor Conference on Wednesday, May 28, 2025, at The Depot Renaissance Hotel in Minneapolis, MN. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guid...

Personalis Reports First Quarter 2025 Financial Results

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2025 ended March 31, 2025, and provided recent business highlights. Recent Business Highlights Delivered 2,184 total molecular tests in the first quarter of 2025, an increase of 52%, compared with 1,441 tests delivered in the fourth quarter of 2024, signifying increasing adoption of Personalis’ technology Highlighted c...

Personalis to Announce First Quarter 2025 Financial Results

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or...
Back to Newsroom